Evaluation of IPM/CS in gram-negative bacillus infections: use of an endotoxin-specific assay.
The subjects were 26 patients hospitalized with severe trauma or burns. Twice daily for seven to 14 days, 1 gm of IPM/CS (a 1:1 combination of imipenem and cilastatin sodium) was administered by intravenous drip infusion to each patient. Clinical outcome was rated excellent in nine patients, good in 12, and fair in five. Bacteria, isolated in 21 of the 26 patients, were eliminated in 18 and decreased in three. Mean endotoxin levels, assessed by the Endospecy method, were reduced from 167.8 pg/ml before treatment to 5.1 pg/ml after treatment. No treatment side effects were noted.
Endo
S
S
Critical Care and Emergency Center, Iwate Medical University, Morioka, Japan.
Inada
K
K
Inoue
Y
Y
Yamada
Y
Y
Fujii
N
N
Nagasawa
T
T
Kikuchi
M
M
Taki
K
K
Hoshi
S
S
Yoshida
M
M
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000097:blood / Q000188:drug therapy*; D015377:Cilastatin / Q000627:therapeutic use*; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D004731:Endotoxins / Q000097:blood*; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D004731:Endotoxins; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination